Jack Bendheim Sells 7,040 Shares of Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $51.37, for a total value of $361,644.80. Following the completion of the sale, the chief executive officer owned 15,560 shares of the company’s stock, valued at approximately $799,317.20. This represents a 31.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, February 26th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $53.73, for a total transaction of $378,259.20.
• On Friday, February 20th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.42, for a total transaction of $361,996.80.
• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total transaction of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.81, for a total value of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.38, for a total value of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total value of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total value of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $268,322.37.

Phibro Animal Health Stock Performance

Shares of Phibro Animal Health stock opened at $54.59 on Friday. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The stock’s fifty day moving average is $43.76 and its two-hundred day moving average is $40.85. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $56.30. The company has a market capitalization of $2.21 billion, a PE ratio of 24.26, a price-to-earnings-growth ratio of 0.84 and a beta of 0.80.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.18. The firm had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health had a net margin of 6.29% and a return on equity of 38.28%. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. As a group, analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th will be given a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.9%. Phibro Animal Health’s dividend payout ratio (DPR) is 21.33%.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PAHC. Morgan Stanley set a $49.00 price target on Phibro Animal Health in a report on Friday, February 6th. Zacks Research lowered Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 9th. JPMorgan Chase & Co. upped their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $37.50.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC grew its stake in Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock valued at $23,959,000 after purchasing an additional 626,492 shares during the last quarter. Capricorn Fund Managers Ltd bought a new stake in shares of Phibro Animal Health in the 3rd quarter valued at about $10,233,000. JPMorgan Chase & Co. boosted its holdings in shares of Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock valued at $9,634,000 after buying an additional 225,110 shares in the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Phibro Animal Health in the 3rd quarter worth approximately $8,931,000. Finally, Ranger Investment Management L.P. raised its stake in shares of Phibro Animal Health by 101.1% during the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock worth $9,143,000 after acquiring an additional 179,975 shares in the last quarter. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.